Please assess the completion status of the following clinical trial:

Trial Title: Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Men or women at least 16 years of age (or minimum age as determined by local regulatory authorities)~* HIV-1 RNA viral load of greater than or equal to 2, 000 copies/mL~* A negative urine pregnancy test at the baseline visit for Women of Child Bearing Potential (WOCBP)~* Effective barrier contraception for WOCBP and males~Exclusion Criteria:~* Suspected or documented active, untreated HIV-1 related opportunistic infection (OI) or other condition requiring acute therapy~* Treatment for an active opportunistic infection, or unexplained temperature \>38.5 degrees Celsius for 7 consecutive days~* Prior treatment with efavirenz, zidovudine or lamivudine or with any other antiretroviral therapy for more than 14 days at any time~* Active alcohol or substance abuse sufficient, in the Investigator's judgment, to prevent adherence to study medication and/or follow up~* Lactating women, or planned pregnancy during the trial period~* Suspected primary (acute) HIV-1 infection~* Previous therapy with a potentially myelosuppressive, neurotoxic, hepatotoxic and/or cytotoxic agent within 30 days prior to randomization or the expected need for such therapy during the study period~* Documented or suspected acute hepatitis or pancreatitis within 30 days prior to randomization~* Significantly elevated liver enzymes or cirrhosis~* Significant neutropenia, anemia or thrombocytopenia~* Malabsorption or an inability to tolerate oral medications~* Symptomatic postural hypotension or severe cardiovascular or cerebrovascular disease~* Certain medications~* Genotypic or phenotypic resistance to efavirenz, zidovudine or lamivudine~* X4- or dual/mixed-tropic virus or repeated assay failure~* Any other clinical condition that, in the Investigator's judgement, would potentially compromise study compliance or the ability to evaluate safety/efficacy

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 3 (Type: ACTIVE_COMPARATOR): None
- 2 (Type: EXPERIMENTAL): Following a review of the interim analysis data, the DSMB recommended to terminate the UK-427,857 300 mg QD arm based on pre-specified protocol non-inferiority criteria not being met for the QD arm versus efavirenz

Based on this trial design, predict the completion outcome and termination type (if applicable).